Medical devices, healthcare technology and the business of care
PMA approval · P250002

Quest Diagnostics AAVrh74 Antibody ELISA CDx

Quest Diagnostics Nichols Institute · Decision date Jul 24, 2025

FDA DECISIONP250002

What did the FDA approve?

FDA records P250002 as an original PMA application. The recorded decision is approval, dated Jul 24, 2025.

FDA approval order statement

Quest Diagnostics AAVrh74 Antibody ELISA CDx is an enzyme-linked immunosorbent in vitro diagnostic assay intended for the semi-quantitative detection of antibodies (IgG) to AAVrh74 capsid in human serum. The test reports an antibody titer, and a semi-quantitative interpretation of the test results derived from the antibody titer. Patients with an AAVrh74 antibody titer less than 1:400 are reported as not elevated for AAVrh74 antibody titers and may be eligible for treatment with the gene therapy. Patients with an AAVrh74 antibody titer greater than or equal to 1:400 are reported as elevated for AAVrh74 antibody titers and are ineligible for treatment with the gene therapy. The test is for prescription use only. The test is intended to be used in conjunction with other available clinical information as an aid to identify patients eligible for treatment with indicated gene therapies.
Regulatory pathway
Original PMA
Clinical specialty
Hematology
Decision date
Jul 24, 2025

FDA source record

Regulatory record facts

Identifier
P250002
Regulatory pathway
Premarket approval application
Product code
QWQ
Decision code
APPR
Decision date
Jul 24, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Assays to detect pre-existing antibodies to adeno-associated virus (AAV) viral vectors.

Product code
QWQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250002 received

    Application receipt date recorded by FDA.

  2. P250002 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250002. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Quest Diagnostics Nichols Institute

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
33608 Ortega Hwy., San Juan Capistrano, CA, 92675

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records